1. < Home

CARE Unit

Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation

Gandhi MM, Nguyen KL, Lake JE, Liao D, Khodabakhshian A, Guerrero M, Shufelt CL, Bairey Merz CN, Jordan WC, Daar ES, Bhattacharya D, Chew KW.[...]

By sjmartinez • February 2, 2024
Acute Cardiovascular Effects of 4th Generation Electronic Cigarettes and Combusted Cigarettes: Implications for Harm Reduction

Nguyen R, Ruedisueli I, Lakhani K, Ma J, Middlekauff HR. Acute Cardiovascular Effects of 4th Generation Electronic Cigarettes and Combusted Cigarettes: Implications for Harm Reduction. J[...]

By sjmartinez • January 11, 2024
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD,[...]

By sjmartinez • November 13, 2023
Daily Oral Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price

Amick AK, Eskibozkurt GE, Hosek SG, Flanagan CF, Landovitz RJ, Jin EY, Wilson CM, Freedberg KA, Weinstein MC, Kazemian P, Paltiel AD, Ciaranello AL, Neilan[...]

By sjmartinez • October 13, 2023
Proprotein convertase subtisilin/kexin 9 (PCSK9) levels decline with HCV therapy in people with HIV/HCV and correlate with inflammation

Gandhi MM, Nguyen KL, Lake JE, Liao D, Khodabakhshian A, Guerrero M, Shufelt CL, Merz CNB, Jordan WC, Daar ES, Bhattacharya D, Chew KW. Proprotein[...]

By sjmartinez • October 4, 2023
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial

Marzinke MA, Hanscom B, Wang Z, Safren SA, Psaros C, Donnell D, Richardson PA, Sullivan P, Eshleman SH, Jennings A, Feliciano KG, Jalil E, Coutinho[...]

By sjmartinez • October 3, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, Ratner L, Henry DH, Cesarman E, DeMarco CE, Costagliola D, Taoufik Y, Ramos[...]

By sjmartinez • August 3, 2023
Phase I trial of the multi-kinase inhibitor cabozantinib, a CYP3A4 substrate, plus CYP3A4 interacting antiretroviral therapy in people living HIV and cancer (AMC087)

Haigentz M, Lee JY, Chiao EY, Aboulafia DM, Ratner L, Ambinder RF, Baiocchi RA, Mitsuyasu RT, Wachsman W, Sparano JA, Rudek MA. Phase I trial[...]

By sjmartinez • August 1, 2023
Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis

Hazra A, Landovitz RJ, Marzinke MA, Quinby C, Creticos C. Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. AIDS. 2023 Jul 4.[...]

By sjmartinez • July 8, 2023
Prevention, treatment and cure of HIV infection

Landovitz RJ, Scott H, Deeks SG. Prevention, treatment and cure of HIV infection. Nat Rev Microbiol. 2023 Jun 21. doi: 10.1038/s41579-023-00914-1. Epub ahead of print.[...]

By sjmartinez • June 22, 2023